Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection

American Journal of Transplantation

Volumn 8, Issue 11, 2008, Pages 2426-2433

  Veldt, B J ^a,b   Poterucha, J J ^a   Watt, K D S ^a   Wiesner, R H ^a   Hay, J E ^a   Kremers, W K ^a   Rosen, C B ^a   Heimbach, J K ^a   Charlton, M R ^a  

^a MAYO CLINIC   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

HCV; Liver transplantation; Outcomes; Treatment

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FIBROSIS; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RNA ANALYSIS;

ANTIVIRAL AGENTS; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGRESSION ANALYSIS; RIBAVIRIN; RISK; TREATMENT OUTCOME;

EID: 53749103476     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02362.x     Document Type: Article

References (20)

1. Davis GL, Lau JY, Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994 23 : 603 613.
2. Sallie R, Cohen AT, Tibbs CJ et al. Recurrence of hepatitis C following orthotopic liver transplantation: A polymerase chain reaction and histological study. J Hepatol 1994 21 : 536 542.
3. Angelico M, Petrolati A, Lionetti R et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007 46 : 1009 1017.
4. Carrion JA, Navasa M, Garcia-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007 132 : 1746 1756.
5. Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003 124 : 642 650.
6. Bizollon T, Pradat P, Mabrut JY et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005 5 : 1909 1913.
7. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: Early preservation injury may predict poor outcome. Liver Transpl 2006 12 : 134 139.
8. Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007 46 : 459 465.
9. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001 33 : 464 470.
10. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods. Am J Epidemiol 2005 162 : 1016 1023.
11. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 : 361 387
12. Veldt BJ, Saracco G, Boyer N et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004 53 : 1504 1508.
13. Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002 8 : 1000 1006.
14. De Vera ME, Smallwood GA, Rosado K et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001 71 : 678 686.
15. Shakil AO, McGuire B, Crippin J et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002 36 : 1253 1258.
16. Berenguer M, Palau A, Fernandez A et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006 12 : 1067 1076.
17. Alberti AB, Belli LS, Airoldi A et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001 7 : 870 876.
18. Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004 77 : 190 194.
19. Bizollon T, Pradat P, Mabrut JY et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007 7 : 448 453.
20. Fewell Z, Davey Smith G, Sterne JA. The impact of residual and unmeasured confounding in epidemiologic studies: A simulation study. Am J Epidemiol 2007 166 : 646 655.